• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

静脉注射人尿激酶原对犬进行冠状动脉溶栓治疗。

Coronary thrombolysis in dogs with intravenously administered human pro-urokinase.

作者信息

Collen D, Stump D, van de Werf F, Jang I K, Nobuhara M, Lijnen H R

出版信息

Circulation. 1985 Aug;72(2):384-8. doi: 10.1161/01.cir.72.2.384.

DOI:10.1161/01.cir.72.2.384
PMID:3924437
Abstract

Coronary thrombolysis was induced by infusion of highly purified human pro-urokinase isolated from a transformed kidney cell line (ACHN) or by infusion of urokinase of urinary origin in anesthetized dogs with 1-hr-old clots in the left anterior descending coronary artery. The clots were induced with a copper coil and thrombolysis was detected by repeat coronary angiography. Intravenous infusion of pro-urokinase at a rate of 10 micrograms/kg/min for 30 min in two dogs did not induce thrombolysis, which was only obtained after 8 and 15 min of its subsequent intracoronary administration. Intravenous infusion of pro-urokinase at a rate of 20 micrograms/kg/min for 30 min in four dogs induced coronary thrombolysis within 23 +/- 2 min (mean +/- SEM). This was not associated with systemic fibrinolytic activation because the alpha 2-antiplasmin and fibrinogen levels did not decrease. Intravenous infusion of urokinase at a rate of 10 micrograms/kg/min for 30 min elicited thrombolysis in four of seven dogs within an average of 19 +/- 2 min. In the other three dogs thrombolysis was only obtained within 11 +/- 3 min of its subsequent intracoronary infusion. Administration of urokinase was associated with systemic fibrinolytic activation as evidenced by a decrease of alpha 2-antiplasmin to about 10% and of fibrinogen to 43 +/- 13% of the preinfusion value. It is concluded that intravenous infusion of pro-urokinase at a sufficiently high rate produces coronary thrombolysis without systemic fibrinolysis in dogs.

摘要

通过输注从转化的肾细胞系(ACHN)中分离出的高度纯化的人尿激酶原,或在左前降支冠状动脉中有1小时陈旧血栓的麻醉犬中输注尿源性尿激酶来诱导冠状动脉溶栓。血栓由铜线圈诱导形成,通过重复冠状动脉造影检测溶栓情况。两只犬以10微克/千克/分钟的速率静脉输注尿激酶原30分钟未诱导溶栓,仅在随后冠状动脉内给药8分钟和15分钟后才出现溶栓。四只犬以20微克/千克/分钟的速率静脉输注尿激酶原30分钟,在23±2分钟(平均值±标准误)内诱导冠状动脉溶栓。这与全身纤溶激活无关,因为α2-抗纤溶酶和纤维蛋白原水平未降低。七只犬中有四只以10微克/千克/分钟的速率静脉输注尿激酶30分钟,平均在19±2分钟内引发溶栓。另外三只犬仅在随后冠状动脉内输注11±3分钟后才出现溶栓。尿激酶给药与全身纤溶激活有关,表现为α2-抗纤溶酶降至约10%,纤维蛋白原降至输注前值的43±13%。结论是,以足够高的速率静脉输注尿激酶原可在犬中产生冠状动脉溶栓而无全身纤溶。

相似文献

1
Coronary thrombolysis in dogs with intravenously administered human pro-urokinase.静脉注射人尿激酶原对犬进行冠状动脉溶栓治疗。
Circulation. 1985 Aug;72(2):384-8. doi: 10.1161/01.cir.72.2.384.
2
Thrombolysis with recombinant human single-chain urokinase-type plasminogen activator (rscu-PA): dose-response in dogs with coronary artery thrombosis.
J Cardiovasc Pharmacol. 1987 Jan;9(1):91-3.
3
Coronary thrombolysis with intravenously administered human tissue-type plasminogen activator produced by recombinant DNA technology.
Circulation. 1984 Mar;69(3):605-10. doi: 10.1161/01.cir.69.3.605.
4
Recombinant single-chain urokinase-type plasminogen activator (rscu-PA) induces thrombolysis and systemic fibrinolysis in a canine model of coronary artery thrombosis.
Thromb Res. 1988 Jul 1;51(1):63-74. doi: 10.1016/0049-3848(88)90283-6.
5
Enhancement of coronary thrombolysis with plasminogen pro-activator by pretreatment with heparin.
Jpn Circ J. 1988 Jan;52(1):72-8. doi: 10.1253/jcj.52.72.
6
Synergistic combinations of recombinant human tissue-type plasminogen activator and human single-chain urokinase-type plasminogen activator. Effect on thrombolysis and reocclusion in a canine coronary artery thrombosis model with high-grade stenosis.重组人组织型纤溶酶原激活剂与人类单链尿激酶型纤溶酶原激活剂的协同组合。对严重狭窄犬冠状动脉血栓形成模型中溶栓及再闭塞的影响。
Circulation. 1989 Feb;79(2):393-9. doi: 10.1161/01.cir.79.2.393.
7
Coronary thrombolysis by intravenous infusion of recombinant single chain urokinase-type plasminogen activator or recombinant urokinase in baboons: effect on regional blood flow, infarct size and hemostasis.
J Am Coll Cardiol. 1986 Jul;8(1):118-24. doi: 10.1016/s0735-1097(86)80101-2.
8
Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro.组织型纤溶酶原激活剂与尿激酶在体外的相对纤维蛋白溶解、纤溶及溶栓特性比较
Thromb Haemost. 1981 Jun 30;45(3):225-9.
9
Thrombolysis with human extrinsic (tissue-type) plasminogen activator in rabbits with experimental jugular vein thrombosis. Effect of molecular form and dose of activator, age of the thrombus, and route of administration.用人外源性(组织型)纤溶酶原激活剂对实验性颈静脉血栓形成的家兔进行溶栓治疗。激活剂分子形式和剂量、血栓形成时间以及给药途径的影响
J Clin Invest. 1983 Feb;71(2):368-76. doi: 10.1172/jci110778.
10
Coronary thrombolysis with recombinant human tissue-type plasminogen activator.
Circulation. 1984 Oct;70(4):700-7. doi: 10.1161/01.cir.70.4.700.

引用本文的文献

1
Thrombolytic efficacy of recombinant human microplasmin in a canine model of copper coil-induced coronary artery thrombosis.重组人微栓酶在犬冠状动脉铜线圈致血栓模型中的溶栓疗效。
J Thromb Thrombolysis. 2010 Jul;30(1):46-54. doi: 10.1007/s11239-009-0400-9.
2
Immunohistological detection of Saruplase (recombinant single-chain urokinase-type plasminogen activator) in normal rat tissue.
Histochemistry. 1991;96(2):163-7. doi: 10.1007/BF00315988.